Royalty Pharma Sub-Manager, LLC
CIK 0002081668 · NEW YORK, NY · Quarter end: 2025-12-31 · Filed on: 2026-08-21 · Open the SEC source ↗
The most recent 13F EDGAR holds under this CIK is 2025 Q4, filed 2026-08-21. Nothing has been filed since — the fund stopped filing, or it files under a different entity now. The positions below are a snapshot of that date, not a current portfolio.
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$171.3M
2025 Q4
Positions
4
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
—
2025 Q4
Top Holdings
CYTK
CYTOKINETICS, INC
36.4%
ZBIO
ZENAS BIOPHARMA, INC.
26.8%
BHVN
BIOHAVEN LTD
19.4%
BCRX
BIOCRYST PHARMACEUTICALS INC
17.5%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.